A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis
about
A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteersApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyVaccines for TB: Lessons from the Past Translating into Future PotentialsVaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challengeCurrent efforts and future prospects in the development of live mycobacteria as vaccinesEmerging infectious diseases: a 10-year perspective from the National Institute of Allergy and Infectious DiseasesMycobacterium tuberculosis dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferationAutoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacyEngineering more stable, selectable marker-free autoluminescent mycobacteria by one stepHitting bacteria at the heart of the central dogma: sequence-specific inhibitionNovel genome polymorphisms in BCG vaccine strains and impact on efficacy.Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants.rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vectorMycobacterial nucleoside diphosphate kinase blocks phagosome maturation in murine RAW 264.7 macrophages.Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trialCharacterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice.Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis chalLatent tuberculosis infection: myths, models, and molecular mechanismsrBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B.Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in miceVaccines: past, present and future.Recombinant BCG as a vaccine vehicle to protect against tuberculosis.Newborn mice vaccination with BCG.HIVA²²² + MVA.HIVA enhances HIV-1-specific immune responses: influence of age and immunization routesNext generation: tuberculosis vaccines that elicit protective CD8+ T cellsImproving the Immunogenicity of the Mycobacterium bovis BCG Vaccine by Non-Genetic Bacterial Surface Decoration Using the Avidin-Biotin SystemImmunogenicity and protective efficacy of a novel recombinant BCG strain overexpressing antigens Ag85A and Ag85B.New TB vaccines: is there a requirement for CD8 T cells?Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis.The success and failure of BCG - implications for a novel tuberculosis vaccine.Immune responses to tuberculosis in developing countries: implications for new vaccines.Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine EfficacyVaccines for tuberculosis: novel concepts and recent progress.Vaccines for bovine tuberculosis: current views and future prospects.Current and novel approaches to vaccine development against tuberculosis.Tuberculosis vaccines: current status and future prospects.Advances in tuberculosis vaccine strategies.Development of vaccines against bovine tuberculosis.
P2860
Q24657992-FE0036BD-5DF3-4DE7-9EFB-ECBCF5516D31Q26798372-5850A10E-91F2-42E9-8A71-DCCF695E54BBQ26996673-C890782A-641E-4940-AB54-2113293A5924Q27331427-9BA54E12-D5B4-42A8-8047-07FC0C791232Q28087077-95A29627-4B6A-4684-8A35-A5A9EC0880B3Q28383084-DD3DF58B-3088-47D0-B078-9E5C4CA7AC71Q28385840-74F7CABA-FE0C-41BB-857E-67A4C882F9ECQ28478840-77C03E25-0883-47F8-8A2A-3E19A7C1B78BQ28543969-316B1398-6CB9-46C3-BD38-6CDDBDC5A70CQ28756986-1363EA65-E41F-4FA5-B022-0C8F800299F0Q33369563-56BC1082-5591-4939-BC74-492653EA9325Q33378483-FC346121-F14E-472E-93E2-65F242AF59C5Q33386020-963E6939-A281-4667-8774-C3ECBD41F14AQ33526364-6D4BD324-29FE-4D88-BD50-8B6DD7CBCB1CQ33724142-FEFB72CB-905B-4005-85D7-F25612DAAAB6Q33793948-7890B19C-0E68-4833-973D-262B8605FDDDQ33826578-46B265C8-61BF-4EE9-B0B3-89D7C26DB742Q33946552-82F738B4-0F1C-4050-8729-7ED8915B4A65Q34177350-583A1BF9-21EA-4776-B39E-2D8DC28ABA25Q34297816-AA11A61F-7F9C-42DE-962A-24BD1168E77EQ34298426-6C489623-8530-4023-A882-75F7698D2BF7Q34309667-A63C19F1-D3D7-4AD3-A447-E11CCB8A405EQ34409178-400179BA-16AA-4DE4-B288-91B1C99C52A5Q34518560-8591ABDD-C6A2-449F-81F5-686F1B45C435Q34983688-B6633CDB-B244-4D0A-BE9D-1652182A7060Q35099708-7CE49198-5A21-4BEC-A3AF-03EF141AE45AQ35881624-45A6BDD3-D0C1-44F7-97C9-18375EA7A1E4Q35915369-1270C2E4-033F-42C0-80F9-61390C648541Q35916176-B7B64612-878E-4E97-84F8-80ED90E56142Q35947967-8D5F0893-3B52-4F31-AB35-BF8DE88E4ED6Q36038717-9782DDE6-BFA3-4BD5-88BA-8C99E4EB3F27Q36191944-CF8336AF-7EC3-4864-88BD-9CAEC8B5156FQ36213975-E361F37B-02E6-4F79-8180-782F87BA95B7Q36219941-FDA78C87-DC36-42FB-BC35-6EF89C7B6E76Q36285657-7D306752-3337-4E90-AD23-A5D7FDCC5CE0Q36350586-8F25C4E4-6601-4A50-8DBA-A487669C3BA5Q36449189-BE1595F2-07A6-4E0C-B1B4-593424ED6868Q36458393-0DF2621E-7581-4353-8631-0FE09681E52DQ36482518-50E5AEB5-1174-4740-A738-1B780742D8BCQ36492602-5886AF09-DAD9-4FE8-AB3F-D56370BB6087
P2860
A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@ast
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@en
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@nl
type
label
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@ast
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@en
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@nl
prefLabel
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@ast
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@en
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@nl
P2860
P3181
P1476
A new vaccine against tubercul ...... odel of pulmonary tuberculosis
@en
P2093
Günter Harth
Marcus A Horwitz
P2860
P304
P3181
P356
10.1128/IAI.71.4.1672-1679.2003
P407
P577
2003-04-01T00:00:00Z